Antibody-drug Conjugates

Development of Antibody-Drug Conjugates (ADCs): Payloads, Linkers, Antibodies, and Artificial Intelligence

by
Development of Antibody-Drug Conjugates (ADCs): Payloads, Linkers, Antibodies, and Artificial Intelligence

Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer treatment, due to their potential for targeted therapy, fewer side effects, broader application, and higher therapeutic index compared to traditional chemotherapy.While ADCs initially focused on hematological malignancies, there has been a clear shift towards solid tumor treatment, with approximately 90% of ADC trials … Read more

Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits

by
Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits

Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits When Qide Pharmaceutical’s FGFR3 ADC drug GQ1011 completed global licensing with a total transaction amount exceeding $13 billion, the biopharmaceutical industry witnessed once again the immense potential of antibody-drug conjugates (ADCs). Meanwhile, the $8.4 billion collaboration between … Read more

The Evolution of Antibody-Drug Conjugates (ADCs)

by
The Evolution of Antibody-Drug Conjugates (ADCs)

–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more

The Evolution of Antibody-Drug Conjugates (ADCs)

by
The Evolution of Antibody-Drug Conjugates (ADCs)

–01– Introduction Antibody-drug conjugates (ADCs) are known as “magic bullets”, precisely targeting tumor cells through antibodies to deliver cytotoxic drugs, combining the precision of targeted therapy with the potent lethality of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field in anti-tumor … Read more

Understanding Antibody-Drug Conjugates (ADCs) and Their Core Components

by
Understanding Antibody-Drug Conjugates (ADCs) and Their Core Components

Click the blue text above to follow us Editor’s Note: With their unique mechanisms of action and powerful efficacy, Antibody-Drug Conjugates (ADCs) have become indispensable treatment methods for various solid tumors and hematological cancers, such as breast cancer. The core component that determines the efficacy of ADCs is undoubtedly the payload. Different payloads exhibit significant … Read more

Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

by
Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

Author Introduction Li Yuejun, Director of the Clinical Trial Center and Research Director of the Oncology Medical Center at Hunan Provincial Traditional Chinese Medicine Hospital. Medical Doctor, Chief Physician, Master’s Supervisor, and High-level Health Talent in Hunan Province. Engaged in clinical oncology, research, and teaching for over 10 years. Specializes in multidisciplinary comprehensive treatment of … Read more

What are ADC Drugs?

by
What are ADC Drugs?

Chemotherapy based on cytotoxic drugs has always been a primary method for treating malignant tumors. However, due to the lack of targeted killing of tumor cells, there are significant toxic reactions, and as the number of chemotherapy cycles increases, tumor resistance also enhances. The challenge of how to target tumor cells to deliver cytotoxic drugs … Read more

Antibody-Drug Conjugates (ADC) – A Review of Linkers (Including a List of Commonly Used Biodegradable Linkers)

by
Antibody-Drug Conjugates (ADC) - A Review of Linkers (Including a List of Commonly Used Biodegradable Linkers)

[Image] Antibody-drug conjugates (ADCs) are a class of emerging anti-cancer drugs that can directly deliver highly cytotoxic molecules to cancer cells. To date, 12 ADC drugs have received market approval. ADCs are formed by the covalent linkage of monoclonal antibodies and cytotoxins through linkers. Research indicates that linkers play a crucial role in ADC drugs, … Read more

Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

by
Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

Antibody-Drug Conjugates (ADCs) are precision anti-cancer drugs that combine the targeting ability of antibodies with potent cytotoxic agents, achieving precise strikes against tumor cells through a “biological missile” design. As of July 2025, a total of 19 ADC drugs have been approved globally, widely used in the treatment of various cancers such as breast cancer … Read more

The Development History of ADC Over 40 Years (Part 3)

by
The Development History of ADC Over 40 Years (Part 3)

The Metabolism Process of ADC The in vivo delivery process of the payload is complicated due to the complex structure of ADCs and their metabolic degradation in the body. After ADC administration, the Drug-to-Antibody Ratio (DAR), bound or free antibodies, albumin conjugates, free payloads, and payload metabolites are all in a highly dynamic state over … Read more